An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients

British Journal of Cancer

Volumn 112, Issue 10, 2015, Pages 1709-1716

  Ichikawa, W ^a   Uehara, K ^b   Minamimura, K ^c   Tanaka, C ^d   Takii, Y ^e   Miyauchi, H ^f   Sadahiro, S ^g   Fujita, K ^h   Moriwaki, T ⁱ   Nakamura, M ^j   Takahashi, T ^a   Tsuji, A ^k   Shinozaki, K ^l   Morita, S ^m   Ando, Y ⁿ   Okutani, Y ^o   Sugihara, M ^o   Sugiyama, T ^p   Ohashi, Y ^q   Sakata, Y ^r  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c MITSUI MEMORIAL HOSPITAL   (Japan)

^d GIFU PREFECTURAL GIFU HOSPITAL   (Japan)

^e NIIGATA CANCER CENTER HOSPITAL   (Japan)

^f CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g TOKAI UNIVERSITY   (Japan)

^h SHOWA UNIVERSITY   (Japan)

ⁱ UNIVERSITY OF TSUKUBA   (Japan)

^j Aizawa Hospital   (Japan)

^k KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^l HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

^m KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁿ NAGOYA UNIVERSITY HOSPITAL   (Japan)

^o DAIICHI SANKYO CO   (Japan)

^p IWATE MEDICAL UNIVERSITY   (Japan)

^q CHUO UNIVERSITY   (Japan)

^r Misawa City Hospital   (Japan)

more..

Author keywords

colorectal cancer; irinotecan; neutropenia; nomogram; UGT1A1

Indexed keywords

BILIRUBIN; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; CAMPTOTHECIN; GLUCURONOSYLTRANSFERASE; UGT1A1 ENZYME;

ADVANCED CANCER; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; DIARRHEA; DRUG SAFETY; ENZYME POLYMORPHISM; FEBRILE NEUTROPENIA; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; NOMOGRAM; OBSERVATIONAL STUDY; OPEN STUDY; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; AGED; ALLELE; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; CLINICAL TRIAL; COLORECTAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; METABOLISM; MIDDLE AGED; NEUTROPENIA; NEUTROPHIL; PATHOLOGY;

AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; BILIRUBIN; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; NEUTROPHILS; NOMOGRAMS; PROSPECTIVE STUDIES;

EID: 84929278540     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.122     Document Type: Article

References (37)

1. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y. (2000). Polymorphisms of UDPglucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 60: 6921-6926
2. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL. (2005). UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11: 1226-1236
3. Chen YJ, Hu F, Li CY, Fang JM, Chu L, Zhang X, Xu Q. (2014). The association of UGT1A1 6 and UGT1A1 28 with irinotecan-induced neutropenia in Asians: a meta-Analysis. Biomarkers 19: 56-62
4. Dias MM, McKinnon RA, Sorich MJ. (2012). Impact of the UGT1A1 28 allele on response to irinotecan: a systematic review and meta-Analysis. Pharmacogenomics 13: 889-899
5. Dias MM, Pignon J-P, Karapetis CS, Boige V, Glimelius B, Kweekel DM, Lara PN, Laurent-Puig P, Martinez-Balibrea E, Páez D, Punt CJA, Redman MW, Toffoli G, Wadelius M, McKinnon RA, Sorich MJ. (2014). The effect of the UGT1A1 28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-Analysis. Pharmacogenomics J 14: 424-431
6. Goto A, Yamada Y, Yasui H, Kato K, Hamaguchi T, Muro K, Shimada Y, Shirao K. (2006). Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 17: 968-973
7. Greenland S. (1995). Dose-response and trend analysis in epidemiology: Alternatives to categorical analysis. Epidemiology 6: 356-365
8. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Jang IJ, Lee DH, Lee JS. (2006). Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24: 2237-2244
9. Hazama S, Mishima H, Tsunedomi R, Okuyama Y, Kato T, Takahashi K, Nozawa H, Ando H, Kobayashi M, Takemoto H, Nagata N, Kanekiyo S, Inoue Y, Hamamoto Y, Fujita Y, Hinoda Y, Okayama N, Oba K, Sakamoto J, Oka M. (2013). UGT1A1 6, 1A7 3, and 1A9 22 genotypes predict severe neutropenia in FOLFIRI-Treated metastatic colorectal cancer in two prospective studies in Japan. Cancer Sci 104: 1662-1669
10. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. (2007). UGT1A1 28 genotype and irinotecan-induced neutropenia: Dose matters. J Natl Cancer Inst 99: 1290-1295
11. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ. (2004). Genetic variants in the UDP-glucuronosyltranferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22: 1382-1388
12. Innocenti F, Ratain MJ. (2006). Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics 7: 1211-1221
13. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ. (2009). Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 27: 2604-2614
14. Innocenti F, Schilsky RL, Ramírez J, Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, Karrison T, Maitland ML, Salgia R, Ratain MJ. (2014). Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol 32: 2328-2334
15. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ. (1998). Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101: 847-854
16. Komatsu Y, Yuki S, Sogabe S, Fukushima H, Iwanaga I, Kudo M, Tateyama M, Meguro T, Uebayashi M, Saga A, Sakata Y, Asaka M. (2011). Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). Oncology 80: 70-75
17. Kweekel D, Guchelaar HJ, Gelderblom H. (2008). Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev 34: 656-669
18. Little RJA, Rubin DB. (2002). Statistical Analysis with Missing Data (ed 2). Wiley Interscience: Hoboken, NJ
19. Liu CY, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS. (2008). UGT1A1 28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 112: 1932-1940
20. Liu X, Cheng D, Kuang Q, Liu G, Xu W. (2013). Association between UGT1A1 28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: A meta-Analysis in Caucasians. PLoS One 8: e58489
21. Liu X, Cheng D, Kuang Q, Liu G, Xu W. (2014). Association of UGT1A1 28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-Analysis in Caucasians. Pharmacogenomics J 14: 120-129
22. Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M, Baiget M. (2004). UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91: 678-682
23. Marcuello E, Páez D, Paré L, Salazar J, Sebio A, Del Rio E, Baiget M. (2011). A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br J Cancer 105: 53-57
24. McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Thibodeau SN, Grothey A, Morton RF, Goldberg RM. (2010). Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: Results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 28: 3227-3233
25. Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N. (2007). Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1 6 and 28. Pharmacogenet Genomics 17: 497-504
26. Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K. (2010). Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11: 853-860
27. Palomaki GE, Bradley LA, Douglas MP, Kolor K, Dotson WD. (2009). Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med 11: 21-34
28. Rouits E, Boisdron-Celle M, Dumont A, Guérin O, Morel A, Gamelin E. (2004). Relevance of different UGT1A1 polymorphisms in irinotecaninduced toxicity: A molecular and clinical study of 75 patients. Clin Cancer Res 10: 5151-5159
29. Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H, Hasegawa R, Kaniwa N, Sawada J, Komamura K, Ueno K, Kamakura S, Kitakaze M, Kitamura Y, Kamatani N, Minami H, Ohtsu A, Shirao K, Yoshida T, Saijo N. (2004). UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-Administered Japanese patients with cancer. Clin Pharmacol Ther 75: 501-515
30. Sai K, Saito Y, Maekawa K, Kim SR, Kaniwa N, Nishimaki-Mogami T, Sawada J, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Matsumura Y, Ohtsu A, Saijo N, Minami H. (2010). Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol 66: 95-105
31. Saltz L. (2013). Systemic therapy for metastatic colorectal cancer. J Natl Compr Canc Netw 11: 649-652
32. Sato T, Ura T, Yamada Y, Yamazaki K, Tsujinaka T, Munakata M, Nishina T, Okamura S, Esaki T, Sasaki Y, Koizumi W, Kakeji Y, Ishizuka N, Hyodo I, Sakata Y. (2011). Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1 28 and/or UGT1A1 6 polymorphisms. Cancer Sci 102: 1868-1873
33. Senter PD, Beam KS, Mixan B, Wahl AF. (2001). Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug. Bioconjug Chem 12: 1074-1080
34. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N. the CPT-11 Gastrointestinal Cancer Study Group. (1993). Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11: 909-913
35. Shiozawa T, Tadokoro J, Fujiki T, Fujino K, Kakihata K, Masatani S, Morita S, Gemma A, Boku N. (2013). Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecanbased chemotherapy: A postmarketing survey. Jpn J Clin Oncol 43: 483-491
36. Toffoli G, Cecchin E, Gasparini G, D'Andrea M, Azzarello G, Basso U, Mini E, Pessa S, De Mattia E, Lo Re G, Buonadonna A, Nobili S, De Paoli P, Innocenti F. (2010). Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 28: 866-871
37. Xu G, Zhang W, Ma MK, McLeod HL. (2002). Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 8: 2605-2611